Bicara Therapeutics Inc. (BCAX)
↓ Download CSVKey ratios (FY2025)
-34.4%
Return on equity
| Metric (FY) | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating Income | -$155.60M | -$82.39M | -$39.89M | — |
| Net Income | -$137.95M | -$68.00M | -$51.98M | — |
| EPS (Diluted) | $-2.52 | $-4.05 | $-89.61 | — |
| Total Assets | $430.99M | $510.00M | $233.98M | — |
| Total Liabilities | $29.54M | $18.12M | $15.47M | — |
| Shareholders' Equity | $401.45M | $491.88M | -$148.77M | -$98.80M |
| Cash & Equivalents | $96.69M | $489.71M | $230.44M | — |
| Operating Cash Flow | -$106.83M | -$74.75M | -$45.63M | — |
| Capital Expenditures | $280.0K | $71.0K | $586.0K | — |
| Shares Outstanding | 56.60M | 54.44M | 640.4K | — |